Cover Image

Guideline-directed medical therapy for heart failure in transthyretin amyloid cardiomyopathy

Cardiac amyloidosis is an underdiagnosed cause of infiltrative cardiomyopathy, leading to heart failure across the spectrum of ejection fractions. Although there are approved disease-modulating therapies for the transthyretin subtype (transthyretin amyloid cardiomyopathy [ATTR-CM]), the role of hear...

Full description

Saved in:
Bibliographic Details
Main Authors: Schwarting, Stéphanie K. (Author) , Bieber, Thomas (Author) , Davies, Daniel R. (Author) , Siepen, Fabian aus dem (Author) , Schwarting, Julian (Author) , Grabmaier, Ulrich (Author) , Massberg, Steffen (Author) , Maurer, Mathew S. (Author) , Kääb, Stefan (Author)
Format: Article (Journal)
Language:English
Published: 18 February 2025
In: Circulation. Heart failure
Year: 2025, Volume: 18, Issue: 4, Pages: ?
ISSN:1941-3297
DOI:10.1161/CIRCHEARTFAILURE.124.011796
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1161/CIRCHEARTFAILURE.124.011796
Verlag, lizenzpflichtig, Volltext: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.124.011796
Get full text
Author Notes:Stéphanie Kristina Schwarting, MD, Thomas Bieber, MD, MDRA, PhD, Daniel R. Davies, MD, Fabian aus dem Siepen, MD, Julian Schwarting, MD, Ulrich Grabmaier, MD, Steffen Massberg, MD, PhD, Mathew S. Maurer, MD, and Stefan Kääb, MD, PhD
Description
Summary:Cardiac amyloidosis is an underdiagnosed cause of infiltrative cardiomyopathy, leading to heart failure across the spectrum of ejection fractions. Although there are approved disease-modulating therapies for the transthyretin subtype (transthyretin amyloid cardiomyopathy [ATTR-CM]), the role of heart failure medications remains uncertain and challenging in clinical practice. Their effects on clinical outcomes, such as mortality and hospitalization, are unknown for ATTR-CM. This review aims to explore the use of these medications in ATTR-CM, considering the disease’s stage and patient-specific issues, such as fluid homeostasis, autonomic dysfunction, conduction disorders, low and fixed stroke volumes, and decreased functional capacity. As our understanding of this condition deepens, it is important to reassess the impact of contemporary heart failure medication in ATTR-CM. Finally, the relevance of guideline recommendations for heart failure drugs based on left ventricular ejection fraction should be reconsidered in the context of ATTR-CM.
Item Description:Gesehen am 10.10.2025
Physical Description:Online Resource
ISSN:1941-3297
DOI:10.1161/CIRCHEARTFAILURE.124.011796

Similar Items